HGH Fragment 176-191: Fat-Loss Peptide Without GH…

HGH Fragment 176-191 is derived from the C-terminal end of the growth hormone molecule—specifically amino acids 176 through 191. This short peptide retains growth hormone's fat-burning properties while discarding the mechanisms responsible for HGH's main side effects: IGF-1 elevation, insulin resistance, and organ growth. It represents one of the most targeted fat loss interventions in peptide pharmacology.

Mechanism: Lipolysis Without the Downsides

The growth hormone molecule has distinct functional regions. The fat-burning region is localized to the C-terminal end (amino acids 176-191). When researchers isolated this fragment and tested it independently, they found it reproduced nearly all of GH's lipolytic activity through beta-3 adrenergic receptor stimulation and direct interaction with fat cell receptors.

Critically, Fragment 176-191 does not bind to the GH receptor strongly enough to trigger IGF-1 production in the liver. IGF-1 elevation is responsible for GH's anabolic effects but also its risks: insulin resistance, potential cell proliferation, and acromegaly features with chronic use. Fragment 176-191 bypasses this pathway entirely.

The peptide inhibits lipogenesis (fat storage) while promoting lipolysis (fat breakdown), particularly in visceral and subcutaneous adipose tissue. It also stimulates adiponectin, an anti-inflammatory adipokine that improves insulin sensitivity—giving it a metabolic profile opposite to full HGH.

AOD-9604: The Modified Version

AOD-9604 is Fragment 176-191 with the addition of a tyrosine residue at the N-terminus, which improves stability and bioavailability. It was developed by Metabolic Pharmaceuticals and reached Phase 3 clinical trials for obesity before the company pivoted. Human trial data confirmed the fat loss effects and clean safety profile but showed less dramatic weight loss than hoped at oral doses, leading to discontinuation of the obesity program.

The trial data remains valuable: AOD-9604 at 1 mg/day orally for 12 weeks produced significant body fat reduction without effects on glucose, IGF-1, thyroid, or other metabolic markers. Subcutaneous dosing at 200-300 mcg/day produces more consistent results than oral due to better bioavailability.

Dosing and Administration

Standard research protocol for HGH Fragment 176-191:

Dose: 200-500 mcg per injection
Frequency: 1-2x daily, ideally in the morning fasted and optionally before exercise
Route: Subcutaneous injection into abdominal fat
Cycle: 8-12 weeks with 4-week breaks

Administration on an empty stomach or in a fasted state maximizes efficacy—insulin blunts the lipolytic signaling. Taking it 30-45 minutes before cardio exercise creates a synergistic fat mobilization effect. The combination of fasted state + Fragment 176-191 + cardiovascular exercise represents the protocol most commonly used by researchers.

What Fragment 176-191 Does Not Do

Understanding the limitations is equally important. This peptide does not:

Build muscle or increase strength (no IGF-1 elevation)
Improve recovery from injury
Affect GH pulsatility or the pituitary
Provide longevity benefits through the GH axis

It is a targeted fat loss tool, best used in a stack where other peptides or compounds address the goals Fragment 176-191 does not cover.

Comparing Fragment 176-191 to Other Fat Loss Peptides

vs. CJC-1295/Ipamorelin: GH secretagogues produce fat loss indirectly through GH elevation and have additional benefits (muscle recovery, sleep, IGF-1). Fragment 176-191 is more targeted but narrower in benefit profile.

vs. Tesamorelin: Tesamorelin is FDA-approved and has clinical validation for visceral fat, but is more expensive and requires more complex protocols. Fragment 176-191 is cheaper and simpler.

vs. AOD-9604: Functionally identical to Fragment 176-191 with a tyrosine addition. AOD-9604 may have marginally better oral bioavailability.

Stacking Considerations

Fragment 176-191 pairs well with peptides that cover its gaps. Adding Ipamorelin at bedtime provides GH pulse benefits for recovery and muscle preservation while Fragment handles daytime fat mobilization. BPC-157 can be added for gut health and systemic repair. This combination provides fat loss, recovery, and tissue repair without the side effect profile of full HGH.

FAQ

Does HGH Fragment 176-191 affect blood sugar? Unlike full HGH, which causes insulin resistance at pharmacological doses, Fragment 176-191 does not affect glucose metabolism and does not require carbohydrate management adjustments in most protocols.

Can Fragment 176-191 be used alongside a caloric surplus? It will still exert lipolytic effects during a surplus, but fat loss is meaningfully greater in a caloric deficit. The peptide is not a substitute for dietary discipline—it accelerates the rate of fat oxidation within whatever caloric context you provide.

Is Fragment 176-191 appropriate for women? Yes. Its targeted mechanism makes it particularly appropriate for women who want fat loss without the hormonal complexity of GH secretagogues. It does not affect estrogen, progesterone, or other sex hormones.

Track your supplements in Optimize.

HGH Fragment 176-191: Fat-Loss Peptide Without GH Side Effects